Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

1. Theralase Technologies’ Unique Value Proposition
Therapeutic Laser Technology (TLT) Division
• Pioneered cold laser therapy, founded in 1995 - Used daily by thousands of practitioners worldwide with millions of patients
successfully treated, supported by clinical trials proving its safety and efficacy.
• FDA, Health Canada and CE approved and manufactured in an ISO -13485 certified facility
• The only laser in the market known to activate of all three known cellular pathways, which allows for cellular healing,
increased blood flow to reduce inflammation and pain reduction.
• High peak power – providing best in class tissue penetration up to 4”
• The TLC-2000 Therapeutic Medical Laser featuring patented biofeedback technology will be released this year providing the
migration from a capital equipment model to a recurring revenue model creating a valuable growing income stream for the
company. Healthcare practitioners will incur a low one-time fee for the equipment, which includes lifetime equipment
warranty and marketing support while in the monthly program. Theralase will share revenues, generated through use of the
laser, with practitioners and monitored over the Internet.
Photo Dynamic Therapy (PDT) Oncology Division
• Research and development of light activated patented Photo Dynamic Compounds (PDC) for the destruction of cancer
• Bladder cancer has been chosen as Theralase’s principal cancer target for its lead PDC compound.
• PDCs proved to be toxic to bladder cancer cells when light activated (100% kill rate).
• Demonstrated the destruction of cancer in a live animal mouse model with >99% efficacy at low concentrations for an under
the skin cancerous tumour, 100% safety was demonstrated.
• $3.98 billion spent annually for Bladder Cancer Treatment in the USA
• Most expensive cancer to treat with a recurrence rate of up to 80%
• 73,000 new cases and over 15,000 deaths in the US each year; worldwide 386,000 new bladder cancer cases occur annually
• Standard treatment unchanged with no new drugs approved since 1998
• 5% of bladder cancer treatment market represents in excess of $200 M annual revenue opportunity (conservative estimate)
• Theralase’s new technology represents a potential “game changer” in bladder cancer treatment
• Technology supported by Dr. Michael Jewett, Professor of Surgery in the Division of Urology at the University of Toronto and
a member of the Department of Surgical Oncology at Princess Margaret Cancer Centre and of the Division of Urology at the
University Health Network
Investment Opportunity
• Theralase Investment to Date: $6 million (research and patented technology)
• Investment Required to Complete FDA Bladder Cancer Phase 1/2a Clinical Study: $6 million
• Time Required to Complete: 3 years
• Value upon Completion: $84 M to $362 M (Average acquisitions completed by big pharma in oncology drugs in the last 3
years, Source: BIO statistics)
• Chance of success: Phase 1 – 70%, Phase 2 – 45%
• Equal partnership with Theralase (50/50 incorporated company)
• Significant Scientific Research and Experimental Development Tax Credits (SR&ED) available
• Return on Investment: 700% to 3000%
Stock Information
• Theralase Technologies Inc. trades on the TSX Venture Exchange under the symbol TLT
• This company overview shall not constitute an offer to sell or the solicitation of any offer to buy any securities. Any such offer
to sell or solicitation of any offer to buy any securities of Theralase will be made only pursuant to subscription documentation
between Theralase and prospective purchasers.